ReviewCancers2026
Next-Generation Immunohistochemical and RNA in Situ Hybridization Assays for Renal Neoplasia: Which Biomarkers Are Ready for Prime Time?
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expanding molecular classification of renal neoplasia has created a growing need for biomarkers that translate biologic insights into practical diagnostic tools. This review focuses on recently introduced immunohistochemical (IHC) and RNA in situ hybridization (RNA-ISH) assays with potential relevance to routine kidney tumor pathology. Biomarkers were selected based on their applicability to conventional formalin-fixed, paraffin-embedded tissue; commercial accessibility and potential for cost-effective implementation; evaluation in substantial tumor cohorts; comparison with established or gold-standard methods; and, where available, validation in independent and/or multi-institutional studies. The reviewed biomarkers encompass markers of cellular lineage and differentiation (L1CAM, FOXI1, and LINC01187); markers of tumor identity, molecular alterations, and metabolic pathway dysregulation (GPNMB, AKR1B10, 2SC, VSTM2A, TRIM63, and Merlin); and prognostic or therapeutically relevant biomarkers (BAP1, HER2, ABCC2, and PD-L1). We critically evaluate their biologic rationale, diagnostic, prognostic, and predictive applications, technical limitations, and current level of validation. By distinguishing biomarkers supported for broader or selective clinical implementation from those requiring additional validation or remaining primarily relevant to defined therapeutic contexts, this review provides a practical framework for their integration into contemporary renal tumor pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.